These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9692307)

  • 41. [Colestasic toxic hepatitis caused by terbinafine: case report].
    Burstein Z; Vildósola H; Lozano Z; Verona R; Vargas G
    Rev Gastroenterol Peru; 2004; 24(4):357-62. PubMed ID: 15614306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study.
    Vena GA; Micali G; Santoianni P; Cassano N; Peruzzi E
    Int J Immunopathol Pharmacol; 2005; 18(4):745-53. PubMed ID: 16388724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Terbinafine: an update.
    Gupta AK; Shear NH
    J Am Acad Dermatol; 1997 Dec; 37(6):979-88. PubMed ID: 9418768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terbinafine-induced subacute cutaneous lupus erythematosus.
    McKay DA; Schofield OM; Benton EC
    Acta Derm Venereol; 2004; 84(6):472-4. PubMed ID: 15844640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.
    Balfour JA; Faulds D
    Drugs; 1992 Feb; 43(2):259-84. PubMed ID: 1372222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day.
    De Backer M; De Vroey C; Lesaffre E; Scheys I; De Keyser P
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S57-63. PubMed ID: 9594939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
    Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hernández N; Ibáñez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK;
    Gastroenterology; 2017 Apr; 152(5):1078-1089. PubMed ID: 28043905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study.
    O'Sullivan DP; Needham CA; Bangs A; Atkin K; Kendall FD
    Br J Clin Pharmacol; 1996 Nov; 42(5):559-65. PubMed ID: 8951186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe liver damage on terbinafine.
    Prescrire Int; 2002 Feb; 11(57):16. PubMed ID: 11985370
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of Candida nail infection with terbinafine.
    Segal R; Kritzman A; Cividalli L; Samra Z; David M; Tiqva P
    J Am Acad Dermatol; 1996 Dec; 35(6):958-61. PubMed ID: 8959955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generalized pustular eruptions due to terbinafine.
    Ozturk G; Turk BG; Karaca N; Karaarslan IK; Ertekin B; Ertam I; Kazandi A; Kandiloglu G
    Cutan Ocul Toxicol; 2012 Mar; 31(1):81-4. PubMed ID: 21888496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hearing impairment associated with oral terbinafine use: a case series and case/non-case analysis in the Netherlands Pharmacovigilance Centre Lareb database and VigiBase™.
    Scholl JH; van Puijenbroek EP
    Drug Saf; 2012 Aug; 35(8):685-91. PubMed ID: 22762134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week).
    Takahata Y; Hiruma M; Shiraki Y; Tokuhisa Y; Sugita T; Muto M
    Mycoses; 2009 Jan; 52(1):72-6. PubMed ID: 18444971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Terbinafine-induced hepatic failure requiring liver transplantation.
    Perveze Z; Johnson MW; Rubin RA; Sellers M; Zayas C; Jones JL; Cross R; Thomas K; Butler B; Shrestha R
    Liver Transpl; 2007 Jan; 13(1):162-4. PubMed ID: 17192859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine.
    Johnstone D; Berger C; Fleckman P
    Arch Intern Med; 2001 Jul; 161(13):1677-8. PubMed ID: 11434801
    [No Abstract]   [Full Text] [Related]  

  • 57. [Oral terbinafine-induced plantar pustular psoriasis].
    Le Guyadec T; Saint-Blancard P; Bosonnet S; Le Vagueresse R; Lanternier G
    Ann Dermatol Venereol; 2000 Mar; 127(3):279-81. PubMed ID: 10804301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Terbinafine-induced subacute cutaneous lupus erythematosus.
    Hivnor CM; Hudkins ML; Bonner B
    Cutis; 2008 Feb; 81(2):156-7. PubMed ID: 18441768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus.
    Tausch I; Decroix J; Gwiezdzinski Z; Urbanowski S; Baran E; Ziarkiewicz M; Levy G; Del Palacio A
    Int J Dermatol; 1998 Feb; 37(2):140-2. PubMed ID: 9542675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short term treatment of dermatophyte onychomycosis with terbinafine.
    Goodfield MJ; Andrew L; Evans EG
    BMJ; 1992 May; 304(6835):1151-4. PubMed ID: 1392793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.